(Q36050471)

11 August 2017

1 reference

title

Use of nifedipine in the treatment of hypertension (English)

1 reference

11 August 2017

1 reference

Roberto Pontremoli

1

1 reference

11 August 2017

Giovanna Leoncini

series ordinal

2

1 reference

11 August 2017

Angelica Parodi

series ordinal

3

1 reference

11 August 2017

language of work or name

1 reference

1 January 2005

1 reference

Expert Review of Cardiovascular Therapy

11 August 2017

published in

1 reference

11 August 2017

volume

3

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

43-50

1 reference

Hypertension treatment and control in five European countries, Canada, and the United States

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate, and weight in mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Nifedipine Improves Left Ventricular Function in Patients with Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Comparison of two calcium blockers on hemodynamics, left ventricular mass, and coronary vasodilatory in advanced hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Nifedipine, but not propranolol, improves left ventricular systolic and diastolic function in patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Effects of antihypertensive drugs on endothelial dysfunction: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Nifedipine. Dose-related increase in mortality in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Critical appraisal of recent studies on nifedipine and other calcium channel blockers in coronary artery disease and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Nifedipine. Relationship between pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Age and severe adverse drug reactions caused by nifedipine and verapamil. Gruppo Italiano di Farmacovigilanza nell' Anziano (GIFA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.43

21 January 2018

Identifiers

DOI

10.1586/14779072.3.1.43

1 reference

11 August 2017

1 reference